# Desmoid tumour

The EU has approved 1 indication of 1 drug in desmoid tumour. None of them needs a biomarker result.

## Approved indications

### No biomarker required

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Nirogacestat](https://oncolabels.com/drugs/nirogacestat) (Ogsiveo) | None | Monotherapy | Any line | Progressing; requiring systemic treatment |

## Label wording

- **Nirogacestat** (Ogsiveo), Desmoid tumour, any line: “Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/ogsiveo-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/desmoid-tumour